Budesonide Tablet, Extended Release
Product Images NDC 68682-309

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 68682-309). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Oceanside Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label

Label for Budesonide extended release tablets, 9 mg, by Oceanside Pharmaceuticals. The label specifies the product as a 30-tablet bottle for oral use, emphasizing the tablets should be swallowed whole without chewing or crushing. It includes storage instructions to keep the container tightly closed and store at controlled room temperature. The label also notes distribution by Oceanside Pharmaceuticals, a Bausch Health US division.*

FDA Label Image

Uceris-1.jpg (Uceris 1)

Chemical structure of budesonide, showing its molecular framework with hydroxyl groups, methyl groups, ketone functional groups, and characteristic rings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.